For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...

Have you been paying attention to current events recently? See how many of these 10 questions you can get right. Compiled by Michael Gonchar and Jeremy Engle A recent study breaks down the ...

It's notable, however, that Arexvy's main rival in the RSV vaccine space – Pfizer's Abrysvo – held up much better in the third quarter, with sales slipping only around 5% to $356 million.

Pfizer's bivalent prefusion F RSV vaccine (Abrysvo) was also granted an expanded approval to include the prevention of lower respiratory tract disease caused by RSV in high-risk adults ages 18 to 59.

Every Doctor, every companion, every enemy. Discover the Whoniverse. Only on BBC iPlayer.

Nestled in family friendly suburb of Corlette is this immaculately maintained single-level brick home. Ideal for families, retirees, and investors alike, this property promises a lifestyle of ease ...

On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.

(NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF ...

(3) You are restricted to three withdrawals a year. If you make more, you earn a lower rate. (4) Account only available to customers resident in Wales. (5) For those living in the branch network ...